| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2017: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
|---|
| Outline of Final Research Achievements |
ADPKD (Autosomal Dominant Polycystic Kidney Disease) is a most frequent hereditary renal disease. Even within the same family, the age leading to end-stage renal failure is different. So it is believed that modifier genes other than disease genes influence disease progression. In this study, I performed exome sequencing on 100 cases and examined the influence of modifier 114 genes. In the mutation group of modifier genes, the increase rate of total kidney volume was significantly lower than that of the control group. So, the variation of modifier genes were considered to be a surrogate marker of tolvaptan efficacy.
|
